|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's range||137.76 - 142.72|
|52-week range||106.86 - 175.91|
|Beta (5Y monthly)||0.69|
|PE ratio (TTM)||20.08|
|Earnings date||27 Oct 2022 - 31 Oct 2022|
|Forward dividend & yield||5.64 (4.20%)|
|Ex-dividend date||13 Oct 2022|
|1y target est||158.61|
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Reata Pharmaceuticals (RETA) is yet to generate product revenues due to the lack of marketed drugs in its portfolio. However, two of its pipeline candidates are close to potential FDA approval.
AbbVie (NYSE: ABBV) will announce its third-quarter 2022 financial results on Friday, October 28, 2022, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.